Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Companies Are Becoming More Creative, Says Astellas India Managing Director Teruo Yasufuku: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Teruo Yasufuku, managing director for Astellas Pharma India, is soft-spoken and carefully measures every answer that he shares with the media. But the law graduate who started his career as a medical representative with Fujisawa in 1983 has been recognized for his leadership skills and the enthusiasm to be the best in the business. Terry, as he is called by his Indian industry contemporaries, can tirelessly talk about Prograf (tacrolimus) - Astellas' flagship transplant brand that notches worldwide sales upwards of $2 billion many years after it has been copied by generic companies. Yasufuku, along with his marketing director Himanshu Dave, proudly point at the back of their business cards, which say 'I Pledge To Donate - kidney, liver, heart, lung, pancreas, corneas.' This, Yasufuku asserts, is Astellas' unflinching commitment to the transplant segment. And, although it is a late entrant and faces intense generic competition, Prograf has a long roadmap laid out for growth in India. Yasufuku shares his wide angle on Astellas' India strategy with PharmAsia News India bureau.
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

SC075136

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel